10-Q: Septerna Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Septerna Inc., a clinical-stage biotechnology company, reported a net loss of $20.5 million for the third quarter of 2024, with significant increases in research and development expenses.

Summary

• Septerna Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) oral small molecule drug discovery.
• The company's proprietary Native Complex Platform aims to unlock the full potential of GPCR therapies.
• Septerna reported a net loss of $20.5 million for the three months ended September 30, 2024, and a net loss of $51.1 million for the nine months ended September 30, 2024.
• Revenue for the three and nine months ended September 30, 2024 was $0.2 million and $0.9 million, respectively, primarily from research services.
• Research and development expenses increased to $17.8 million for the three months ended September 30, 2024, and $46.0 million for the nine months ended September 30, 2024.
• General and administrative expenses were $4.9 million for the three months ended September 30, 2024, and $10.9 million for the nine months ended September 30, 2024.
• The company completed its initial public offering (IPO) in October 2024, raising approximately $302.6 million in net proceeds.
• As of September 30, 2024, Septerna had $137.5 million in cash, cash equivalents, and marketable securities.
• The company believes its existing cash, cash equivalents, and marketable securities, together with the net proceeds from its IPO, will be sufficient to fund operations into the second half of 2027.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the successful IPO and strong cash position are positive, the significant net losses and increasing expenses raise concerns. The company is still in the early stages of development, which adds to the uncertainty.

Positives

• The company successfully completed its IPO in October 2024, raising significant capital.
• Septerna has a strong cash position of $137.5 million as of September 30, 2024, which, combined with IPO proceeds, is expected to fund operations into the second half of 2027.
• The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs.

Negatives

• Septerna has incurred significant operating losses since its inception and expects to continue to incur losses for the foreseeable future.
• Research and development expenses have increased significantly, reflecting the high cost of drug development.
• The company has a limited operating history and has not yet generated revenue from product sales.

Risks

• The company is early in its development efforts and has only recently initiated early clinical studies.
• Preclinical and clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes.
• The company may encounter substantial delays in the commencement, enrollment, or completion of planned clinical trials.
• Serious adverse events or undesirable side effects of product candidates may be identified during development or after approval.
• The company relies on third-party manufacturers, CROs, CMOs, and suppliers, and their failure to comply with requirements could adversely affect the business.
• The company faces substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than Septerna.
• The company may require substantial additional funding in the future, and if unable to raise capital, may be forced to delay, reduce, or terminate certain programs.
• The company's proprietary Native Complex Platform is based on novel technologies that are unproven and may not result in approvable or marketable products.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities, together with the net proceeds from its IPO, will be sufficient to fund its operations and capital expenditure requirements into the second half of 2027.

Management Comments

• The company is pioneering a new era of GPCR oral small molecule drug discovery.
• The company's industrial-scale platform aims to unlock the full potential of GPCR therapies.
• The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary and novel products and product candidates. Septerna is competing with major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.

Comparison to Industry Standards

• Several companies are developing therapies for hypoparathyroidism, including Ascendis Pharma (YORVIPATH), Takeda (NATPARA), and Amolyt Pharma (eneboparatide, acquired by AstraZeneca).
• Multiple companies are pursuing small molecule MRGPRX2 inhibitors, such as Escient Pharmaceuticals (acquired by Incyte), Evommune, and BioArdis.
• Companies like Byondis and Crinetics are working on TSHR compounds, while others like Immunovant, Amgen, Viridian, Argenx, Roche, Lassen Therapeutics, Tourmaline Bio, Sling Therapeutics, and Acelyrin are developing therapies for Graves disease and thyroid eye disease.
• The market for incretin receptor agonists is competitive, with products like Ozempic, Wegovy, Trulicity, Mounjaro, and Zepbound, and companies like Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Roche, and Viking developing similar therapies.

Related Party Transactions

• The company issued Series B Convertible Preferred Stock to Third Rock Ventures VI, L.P., RA Capital Management, L.P., and Samsara BioCapital, L.P.
• The company has a service agreement with Third Rock Ventures, LLC, under which TRV provides consulting services to the company.

Stakeholder Impact

• Shareholders: The company's financial performance and future prospects will impact shareholder value.
• Employees: The company's growth and success will affect employment opportunities and job security.
• Customers: The company's product development efforts will impact the availability of new treatments for patients.
• Suppliers: The company's reliance on third-party manufacturers and suppliers will affect their business.

Next Steps

• Continue to advance product candidates through preclinical studies and into clinical trials.
• Attract, hire, and retain additional personnel.
• Operate as a public company, including compliance with SEC rules and regulations.
• Continue research and development efforts and expand the pipeline of product candidates.
• Seek regulatory approvals for product candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure to commercialize any product candidate for which marketing approval is obtained.

Key Dates

Keywords

GPCR, biotechnology, clinical-stage, drug discovery, small molecule, Native Complex Platform, hypoparathyroidism, SEP-786, PTH1R, IPO, research and development, clinical trials, financial results